v3.25.3
Other Gains and Losses, and Litigation (Details) - EUR (€)
€ in Millions
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Analysis of income and expense [abstract]    
Other gains and litigation [1] € 57 € 450 [2]
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.